Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by SkywalkerofLukeon Mar 28, 2023 3:58pm
115 Views
Post# 35365369

Interview with CEO on Upcoming Clinical Trial

Interview with CEO on Upcoming Clinical Trial

A US survey found that 5% of people (approximately 12.2 million adults) reported experiencing chronic cough in the previous 12 months. The chronic cough market is expected to reach $11.38B by 2029.


I’ve been following AGN.c AGNPF (a clinical stage drug development company). This interview with their CEO gives updates on the previously announced 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough that will begin in Q3.


There’s clearly a huge opportunity in finding a solution to chronic cough and AGN is poised to find the solution.


https://www.youtube.com/watch?v=zpvV0-fELgc

<< Previous
Bullboard Posts
Next >>